MMS, an award-winning, data-focused clinical research organization (CRO), has announced its acquisition of Exploristics. Read more
Exploristics Retains Silver Diversity Mark and achieves Belfast Business Promise Member Status
Exploristics is pleased to announce a new collaboration with the Biostatistics Research Group at the Population Health Sciences Institute at Newcastle University
IDEA Pharma and Exploristics are delighted to announce a new collaboration to integrate analytics and advanced simulation methods into the strategic decision-making process of biopharmaceutical development.
Exploristics and Exonate are pleased to announce the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease using study simulation platform, KerusCloud.
For January 2024, Exploristics is pleased to be launching the Pulmonary Suite, a collection of robust pulmonary disease specific data models for targeted clinical trial design optimisation.
Exploristics is pleased to announce a new collaboration agreement with ENA Respiratory to embed smart study design using simulation-guided clinical trial design platform, KerusCloud
In June, an Exploristics team comprised of Aiden Flynn, Kim Hacquoil, Sam Matthews, Andrew Mills and Katie Taiyari were delighted to attend the annual PSI Conference 2023 in Hammersmith.
We are pleased to announce the global launch of the KerusCloud Spring 2023 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics is delighted to be participating in Belfast City Council’s new inclusive growth initiative, the Belfast Business Promise.
Exploristics has completed an Innovate UK award supporting further R&D for KerusCloud.
Exploristics are pleased to be participating in the first Effective Statistician Conference which will take place on April 25th, 2023
We are pleased to announce the global launch of the KerusCloud Spring 2022 release, Exploristics’ ground-breaking clinical trial design platform.
We are proud to announce that Exploristics has attained the Silver Diversity Charter Mark.
Integration of Clarivate Cortellis data with cloud-based simulation platform, KerusCloud, for smarter, more efficient study design
Exploristics is delighted that its work on the COVASE trial with the Crick, UCH and Target to Treatment has won the 2021 Sir David Cooksey prize
Exploristics is pleased to announce today a collaboration with Renovion using Exploristics’ innovative study simulation software platform KerusCloud
Innovate UK grants Smart Award to expand KerusCloud.
Exploristics is delighted to welcome Susan Clement-Davies to the Board as a Non-Executive Director. Susan is an experienced life sciences financier
We are delighted to announce that Exploristics’ CEO, Dr Aiden Flynn, has been appointed Commercial Director on the Board of Directors at PSI.
Exploristics is pleased to announce a new collaboration agreement with Istesso to embed study simulation using innovative software platform KerusCloud.
We are pleased to announce the global launch of the KerusCloud Spring 2021 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics have joined the WISE Campaign, and are delighted to be part of the journey promoting STEM, equality, diversity and inclusion.
Exploristics signs collaboration agreement with Galapagos to embed study simulation into clinical development with innovative software platform KerusCloud.
We’re delighted to have been awarded membership of the NIWISE hub.
Exploristics joins the Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT).
Exploristics has been recognised as a Platinum Level Innovator by Innovate NI.
Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.
Exploristics is pleased to announce its involvement with the COVASE trial evaluating cystic fibrosis drug, Dornase alfa, as a treatment for COVID-19.
Exploristics is pleased to have become a member of the UK BioIndustry Association.
We are hosting an initial series of webinars following the global launch of KerusCloud 2.
We are pleased to announce the global launch of the next generation of the ground-breaking KerusCloud 2.
Exploristics receives Bronze Diversity Charter Mark
Exploristics is pleased announce that we have joined the Avicenna Alliance.
Exploristics has won a prestigious Innovate UK Smart award for £340K.
Exploristics nominated for the Innovation of the Year award at the Irish Pharma Industry Awards 2019.
Exploristics has been awarded the Bronze Diversity Mark Charter Mark.
Exploristics is celebrating its ten year anniversary!
Two new announcements this week from Exploristics.
MMS, an award-winning, data-focused clinical research organization (CRO), has announced its acquisition of Exploristics. Read more
Exploristics Retains Silver Diversity Mark and achieves Belfast Business Promise Member Status
Exploristics is pleased to announce a new collaboration with the Biostatistics Research Group at the Population Health Sciences Institute at Newcastle University
IDEA Pharma and Exploristics are delighted to announce a new collaboration to integrate analytics and advanced simulation methods into the strategic decision-making process of biopharmaceutical development.
Exploristics and Exonate are pleased to announce the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease using study simulation platform, KerusCloud.
For January 2024, Exploristics is pleased to be launching the Pulmonary Suite, a collection of robust pulmonary disease specific data models for targeted clinical trial design optimisation.
Exploristics is pleased to announce a new collaboration agreement with ENA Respiratory to embed smart study design using simulation-guided clinical trial design platform, KerusCloud
In June, an Exploristics team comprised of Aiden Flynn, Kim Hacquoil, Sam Matthews, Andrew Mills and Katie Taiyari were delighted to attend the annual PSI Conference 2023 in Hammersmith.
We are pleased to announce the global launch of the KerusCloud Spring 2023 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics is delighted to be participating in Belfast City Council’s new inclusive growth initiative, the Belfast Business Promise.
Exploristics has completed an Innovate UK award supporting further R&D for KerusCloud.
Exploristics are pleased to be participating in the first Effective Statistician Conference which will take place on April 25th, 2023
We are pleased to announce the global launch of the KerusCloud Spring 2022 release, Exploristics’ ground-breaking clinical trial design platform.
We are proud to announce that Exploristics has attained the Silver Diversity Charter Mark.
Integration of Clarivate Cortellis data with cloud-based simulation platform, KerusCloud, for smarter, more efficient study design
Exploristics is delighted that its work on the COVASE trial with the Crick, UCH and Target to Treatment has won the 2021 Sir David Cooksey prize
Exploristics is pleased to announce today a collaboration with Renovion using Exploristics’ innovative study simulation software platform KerusCloud
Innovate UK grants Smart Award to expand KerusCloud.
Exploristics is delighted to welcome Susan Clement-Davies to the Board as a Non-Executive Director. Susan is an experienced life sciences financier
We are delighted to announce that Exploristics’ CEO, Dr Aiden Flynn, has been appointed Commercial Director on the Board of Directors at PSI.
Exploristics is pleased to announce a new collaboration agreement with Istesso to embed study simulation using innovative software platform KerusCloud.
We are pleased to announce the global launch of the KerusCloud Spring 2021 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics have joined the WISE Campaign, and are delighted to be part of the journey promoting STEM, equality, diversity and inclusion.
Exploristics signs collaboration agreement with Galapagos to embed study simulation into clinical development with innovative software platform KerusCloud.
We’re delighted to have been awarded membership of the NIWISE hub.
Exploristics joins the Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT).
Exploristics has been recognised as a Platinum Level Innovator by Innovate NI.
Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.
Exploristics is pleased to announce its involvement with the COVASE trial evaluating cystic fibrosis drug, Dornase alfa, as a treatment for COVID-19.
Exploristics is pleased to have become a member of the UK BioIndustry Association.
We are hosting an initial series of webinars following the global launch of KerusCloud 2.
We are pleased to announce the global launch of the next generation of the ground-breaking KerusCloud 2.
Exploristics receives Bronze Diversity Charter Mark
Exploristics is pleased announce that we have joined the Avicenna Alliance.
Exploristics has won a prestigious Innovate UK Smart award for £340K.
Exploristics nominated for the Innovation of the Year award at the Irish Pharma Industry Awards 2019.
Exploristics has been awarded the Bronze Diversity Mark Charter Mark.
Exploristics is celebrating its ten year anniversary!
Two new announcements this week from Exploristics.
MMS, an award-winning, data-focused clinical research organization (CRO), has announced its acquisition of Exploristics. Read more
Exploristics Retains Silver Diversity Mark and achieves Belfast Business Promise Member Status
Exploristics is pleased to announce a new collaboration with the Biostatistics Research Group at the Population Health Sciences Institute at Newcastle University
IDEA Pharma and Exploristics are delighted to announce a new collaboration to integrate analytics and advanced simulation methods into the strategic decision-making process of biopharmaceutical development.
Exploristics and Exonate are pleased to announce the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease using study simulation platform, KerusCloud.
For January 2024, Exploristics is pleased to be launching the Pulmonary Suite, a collection of robust pulmonary disease specific data models for targeted clinical trial design optimisation.
Exploristics is pleased to announce a new collaboration agreement with ENA Respiratory to embed smart study design using simulation-guided clinical trial design platform, KerusCloud
In June, an Exploristics team comprised of Aiden Flynn, Kim Hacquoil, Sam Matthews, Andrew Mills and Katie Taiyari were delighted to attend the annual PSI Conference 2023 in Hammersmith.
We are pleased to announce the global launch of the KerusCloud Spring 2023 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics is delighted to be participating in Belfast City Council’s new inclusive growth initiative, the Belfast Business Promise.
Exploristics has completed an Innovate UK award supporting further R&D for KerusCloud.
Exploristics are pleased to be participating in the first Effective Statistician Conference which will take place on April 25th, 2023
We are pleased to announce the global launch of the KerusCloud Spring 2022 release, Exploristics’ ground-breaking clinical trial design platform.
We are proud to announce that Exploristics has attained the Silver Diversity Charter Mark.
Integration of Clarivate Cortellis data with cloud-based simulation platform, KerusCloud, for smarter, more efficient study design
Exploristics is delighted that its work on the COVASE trial with the Crick, UCH and Target to Treatment has won the 2021 Sir David Cooksey prize
Exploristics is pleased to announce today a collaboration with Renovion using Exploristics’ innovative study simulation software platform KerusCloud
Innovate UK grants Smart Award to expand KerusCloud.
Exploristics is delighted to welcome Susan Clement-Davies to the Board as a Non-Executive Director. Susan is an experienced life sciences financier
We are delighted to announce that Exploristics’ CEO, Dr Aiden Flynn, has been appointed Commercial Director on the Board of Directors at PSI.
Exploristics is pleased to announce a new collaboration agreement with Istesso to embed study simulation using innovative software platform KerusCloud.
We are pleased to announce the global launch of the KerusCloud Spring 2021 release, Exploristics’ ground-breaking clinical trial design platform.
Exploristics have joined the WISE Campaign, and are delighted to be part of the journey promoting STEM, equality, diversity and inclusion.
Exploristics signs collaboration agreement with Galapagos to embed study simulation into clinical development with innovative software platform KerusCloud.
We’re delighted to have been awarded membership of the NIWISE hub.
Exploristics joins the Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT).
Exploristics has been recognised as a Platinum Level Innovator by Innovate NI.
Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.
Exploristics is pleased to announce its involvement with the COVASE trial evaluating cystic fibrosis drug, Dornase alfa, as a treatment for COVID-19.
Exploristics is pleased to have become a member of the UK BioIndustry Association.
We are hosting an initial series of webinars following the global launch of KerusCloud 2.
We are pleased to announce the global launch of the next generation of the ground-breaking KerusCloud 2.
Exploristics receives Bronze Diversity Charter Mark
Exploristics is pleased announce that we have joined the Avicenna Alliance.
Exploristics has won a prestigious Innovate UK Smart award for £340K.
Exploristics nominated for the Innovation of the Year award at the Irish Pharma Industry Awards 2019.
Exploristics has been awarded the Bronze Diversity Mark Charter Mark.
Exploristics is celebrating its ten year anniversary!
Two new announcements this week from Exploristics.